Skip to content

Discontinued — last reported Q4 '25

Interest Expense at other companies

Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$3.46M+529%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
-$3.77M+31.3%
Precigen logo
PrecigenPGEN
$2.91M+290,700%
Arcutis Biotherapeutics, Inc. logo
Arcutis Biotherapeutics, Inc.ARQT
$4.37M+46.5%
LQD
Liquidia CorporationLQDA
$6.49M+39.1%
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$1.75M+101%

Other financials

Income statement

See full
Revenue$53.0K-97.3%
Operating income-$14.9M-88.7%
Net income-$15.8M-92.6%
EPS (diluted)-$1.20-62.2%

Balance sheet

See full
Cash & equivalents$206.4M+173%
Total debt$584.0K
Total equity$232.3M+318%
Total assets$263.8M+232%

Cash flow

See full
Operating cash flow-$10.9M-60.5%
CapEx--100%
Free cash flow-$2.7M+72.0%

Valuation

See full
Market cap$1.86B+468%

Profitability

See full
Operating margin-183.2%-13.5pp
Net margin71.7%+40.4pp
FCF margin-99.8%-34.2pp

Returns & leverage

See full
Return on equity-34.2%
Debt / equity
Current ratio28.9×+20.0×

Where this comes from

Reported directly by Palvella Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:InterestExpenseDebt.

The official record: Palvella Therapeutics’s 10-K, filed March 31, 2026, on SEC EDGAR. View the filing →

Ask your AI about Palvella Therapeutics's interest expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Palvella Therapeutics's interest expense?
Palvella Therapeutics (PVLA) reported interest expense of $0 in Q4 2025.
How has Palvella Therapeutics's interest expense changed year-over-year?
Palvella Therapeutics's interest expense decreased by 100.0% year-over-year, from $181K to $0.
What does interest expense mean?
Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.